Overview

Radiolabelled IV and Oral Metabolism Study of F901318

Status:
Withdrawn
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
Open label radiolabelled metabolism study of intravenous and oral solution forms of F901318. Five healthy male subjects will receive IV and five will receive an oral solution. Blood, urine and faeces will be collected over a period adequate to obtain 90% recovery of parent compound and to determine the metabolic profile of both IV and oral forms.
Phase:
Phase 1
Details
Lead Sponsor:
F2G Biotech GmbH
F2G Ltd.
Collaborator:
Quotient Clinical
Treatments:
Olorofim